ASTI · Ascent Solar Technologies, Inc.

The option grant was approved by the Issuer's Board of Directors on July 2, 2026.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 7/31/26, 1/3 - 7/31/27, 1/3 - 7/31/28. Any outstanding and unvested options will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The option grant was approved by the Issuer's Board of Directors on July 2, 2026.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 7/31/26, 1/3 - 7/31/27, 1/3 - 7/31/28. Any outstanding and unvested options will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The option grant was approved by the Issuer's Board of Directors on July 2, 2026.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 7/31/26, 1/3 - 7/31/27, 1/3 - 7/31/28. Any outstanding and unvested options will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The option grant was approved by the Issuer's Board of Directors on July 2, 2026.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 7/31/27, 1/3 - 7/31/28, 1/3 - 7/31/29. Any outstanding and unvested options will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The option grant was approved by the Issuer's Board of Directors on July 2, 2026.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 7/31/27, 1/3 - 7/31/28, 1/3 - 7/31/29. Any outstanding and unvested options will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The option grant was approved by the Issuer's Board of Directors on July 2, 2026.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 7/31/26, 1/3 - 7/31/27, 1/3 - 7/31/28. Any outstanding and unvested options will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The option grant was approved by the Issuer's Board of Directors on July 2, 2026.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 7/31/27, 1/3 - 7/31/28, 1/3 - 7/31/29. Any outstanding and unvested options will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

On 5/22/2026, the Reporting Person converted 61 shares of Series 1C preferred stock (including accrued dividends thereon) into an aggregate 28,343 shares of common stock.

On October 17, 2024, the Reporting Person entered into a securities purchase agreement to purchase up to 965 shares of the Company's newly issued Series 1C convertible preferred stock at a purchase price of $1,000 per Series 1C preferred share. The parties only closed on the purchase of 150 Series 1C preferred shares. The stated value and accrued dividends on Series 1C preferred shares is convertible into common stock beginning on 4/18/2025 at a conversion price of $2.50 per common share.

On 5/22/2026, the Reporting Person converted 61 shares of Series 1C preferred stock (including accrued dividends thereon) into an aggregate 28,343 shares of common stock.

The Series 1C preferred stock is perpetual and therefore has no expiration date.

Each Series 1C share has a Stated Value of $1,000. The Stated Value (and accrued dividends thereon) are convertible into shares of common stock based at the conversion price of $2.50 per common share.

On October 17, 2024, the Reporting Person entered into a securities purchase agreement to purchase up to 965 shares of the Company's newly issued Series 1C convertible preferred stock at a purchase price of $1,000 per Series 1C preferred share. The parties only closed on the purchase of 150 Series 1C preferred shares. The stated value and accrued dividends on Series 1C preferred shares is convertible into common stock beginning on 4/18/2025 at a conversion price of $2.50 per common share.

On 12/15/2025, the Reporting Person converted 89 shares of Series 1C preferred stock (including accrued dividends thereon) into an aggregate 38,827 shares of common stock.

The Series 1C preferred stock is perpetual and therefore has no expiration date.

Each Series 1C share has a Stated Value of $1,000. The Stated Value (and accrued dividends thereon) are convertible into shares of common stock based at the conversion price of $2.50 per common share.

On 12/15/2025, the Reporting Person converted 89 shares of Series 1C preferred stock (including accrued dividends thereon) into an aggregate 38,827 shares of common stock.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on June 2, 2025.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 6/30/2025, 1/3 - 6/30/2026, 1/3 - 6/30/2027.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on June 2, 2025.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 6/30/2025, 1/3 - 6/30/2026, 1/3 - 6/30/2027.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on June 2, 2025.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 6/30/2025, 1/3 - 6/30/2026, 1/3 - 6/30/2027.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on June 2, 2025.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 6/30/2025, 1/3 - 6/30/2026, 1/3 - 6/30/2027.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on June 2, 2025.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 6/30/2025, 1/3 - 6/30/2026, 1/3 - 6/30/2027.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on June 2, 2025.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 6/30/2025, 1/3 - 6/30/2026, 1/3 - 6/30/2027.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on June 2, 2025.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 6/30/2025, 1/3 - 6/30/2026, 1/3 - 6/30/2027.

425 (adjusted for a 1 share for 100 reverse stock split effected on August 14, 2024) of the previously shares reported are restricted stock units ("RSUs") granted 1/17/2024. Each RSU represents a contingent right to receive one share of ASTI common stock.

One third of the RSU's will vest on each of 3/31/2024, 1/1/2025 and 1/1/2026. Any outstanding and unvested RSU's will accelerate and fully vest upon the earlier of (i) a change of control or (ii) the termination of Mr. Gulati's employment for any reason other than (x) by the Company for cause or (y) by Mr. Gulati without good reason.

Reflects 49 shares withheld by the Issuer to satisfy tax withholding obligations related to an RSU vest on 1/1/2025.

On October 17, 2024, the Reporting Person purchased 35 shares of the Company's newly issued Series 1C convertible preferred stock at a purchase price of $1,000 per Series 1C share. The Series 1C preferred stock is convertible into common stock beginning on 4/18/2025 at a per share conversion price of $2.50 per common share.

The Series 1C preferred stock is perpetual and therefore has no expiration date.

Each Series 1C share has a Stated Value of $1,000 which is convertible into 400 shares of common stock based upon the conversion price of $2.50 per common share. The 35 shares of Series 1C preferred shares purchased would be convertible into an aggregate 14,000 shares of common stock, except that the Series 1C preferred shares have a 4.99% beneficial ownership blocker on the conversion feature. The number of shares that the Reporting Person could convert and/or vote at any time, therefore, would be limited to that number of common shares (which when combined with all other common shares then beneficially owned) that would not increase the Reporting Person's beneficial ownership of common stock above 4.99% of the Company's then outstanding common stock.

On October 17, 2024, the Reporting Person purchased 25 shares of the Company's newly issued Series 1C convertible preferred stock at a purchase price of $1,000 per Series 1C share. The Series 1C preferred stock is convertible into common stock beginning on 4/18/2025 at a per share conversion price of $2.50 per common share.

The Series 1C preferred stock is perpetual and therefore has no expiration date.

Each Series 1C share has a Stated Value of $1,000 which is convertible into 400 shares of common stock based upon the conversion price of $2.50 per common share. The 25 shares of Series 1C preferred shares purchased would be convertible into an aggregate 10,000 shares of common stock, except that the Series 1C preferred shares have a 4.99% beneficial ownership blocker on the conversion feature. The number of shares that the Reporting Person could convert and/or vote at any time, therefore, would be limited to that number of common shares (which when combined with all other common shares then beneficially owned) that would not increase the Reporting Person's beneficial ownership of common stock above 4.99% of the Company's then outstanding common stock.

On October 17, 2024, the Reporting Person purchased 5 shares of the Company's newly issued Series 1C convertible preferred stock at a purchase price of $1,000 per Series 1C share. The Series 1C preferred stock is convertible into common stock beginning on 4/18/2025 at a per share conversion price of $2.50 per common share.

The Series 1C preferred stock is perpetual and therefore has no expiration date.

Each Series 1C share has a Stated Value of $1,000 which is convertible into 400 shares of common stock based upon the conversion price of $2.50 per common share. The 5 shares of Series 1C preferred shares purchased would be convertible into an aggregate 2,000 shares of common stock, except that the Series 1C preferred shares have a 4.99% beneficial ownership blocker on the conversion feature. The number of shares that the Reporting Person could convert and/or vote at any time, therefore, would be limited to that number of common shares (which when combined with all other common shares then beneficially owned) that would not increase the Reporting Person's beneficial ownership of common stock above 4.99% of the Company's then outstanding common stock.

On October 17, 2024, the Reporting Person purchased 10 shares of the Company's newly issued Series 1C convertible preferred stock at a purchase price of $1,000 per Series 1C share. The Series 1C preferred stock is convertible into common stock beginning on 4/18/2025 at a per share conversion price of $2.50 per common share.

The Series 1C preferred stock is perpetual and therefore has no expiration date.

Each Series 1C share has a Stated Value of $1,000 which is convertible into 400 shares of common stock based upon the conversion price of $2.50 per common share. The 10 shares of Series 1C preferred shares purchased would be convertible into an aggregate 4,000 shares of common stock, except that the Series 1C preferred shares have a 4.99% beneficial ownership blocker on the conversion feature. The number of shares that the Reporting Person could convert and/or vote at any time, therefore, would be limited to that number of common shares (which when combined with all other common shares then beneficially owned) that would not increase the Reporting Person's beneficial ownership of common stock above 4.99% of the Company's then outstanding common stock.

On October 17, 2024, the Reporting Person purchased 965 shares of the Company's newly issued Series 1C convertible preferred stock at a purchase price of $1,000 per Series 1C share. The Series 1C preferred stock is convertible into common stock beginning on 4/18/2025 at a per share conversion price of $2.50 per common share.

The Series 1C preferred stock is perpetual and therefore has no expiration date.

Each Series 1C share has a Stated Value of $1,000 which is convertible into 400 shares of common stock based upon the conversion price of $2.50 per common share. The 965 Series 1C preferred shares purchased would be convertible into an aggregate 386,000 shares of common stock, except that the Series 1C preferred shares have a 4.99% beneficial ownership blocker on the conversion feature. The number of shares that the Reporting Person could convert and/or vote at any time, therefore, would be limited to that number of common shares (which when combined with all other common shares then beneficially owned) that would not increase the Reporting Person's beneficial ownership of common stock above 4.99% of the Company's then outstanding common stock.

On October 17, 2024, the Reporting Person purchased 55 shares of the Company's newly issued Series 1C convertible preferred stock at a purchase price of $1,000 per Series 1C share. The Series 1C preferred stock is convertible into common stock beginning on 4/18/2025 at a per share conversion price of $2.50 per common share.

The Series 1C preferred stock is perpetual and therefore has no expiration date.

Each Series 1C share has a Stated Value of $1,000 which is convertible into 400 shares of common stock based upon the conversion price of $2.50 per common share. The 55 shares of Series 1C preferred shares purchased would be convertible into an aggregate 22,000 shares of common stock, except that the Series 1C preferred shares have a 4.99% beneficial ownership blocker on the conversion feature. The number of shares that the Reporting Person could convert and/or vote at any time, therefore, would be limited to that number of common shares (which when combined with all other common shares then beneficially owned) that would not increase the Reporting Person's beneficial ownership of common stock above 4.99% of the Company's then outstanding common stock.

On October 17, 2024, the Reporting Person purchased 35 shares of the Company's newly issued Series 1C convertible preferred stock at a purchase price of $1,000 per Series 1C share. The Series 1C preferred stock is convertible into common stock beginning on 4/18/2025 at a per share conversion price of $2.50 per common share.

The Series 1C preferred stock is perpetual and therefore has no expiration date.

Each Series 1C share has a Stated Value of $1,000 which is convertible into 400 shares of common stock based upon the conversion price of $2.50 per common share. The 35 shares of Series 1C preferred shares purchased would be convertible into an aggregate 14,000 shares of common stock, except that the Series 1C preferred shares have a 4.99% beneficial ownership blocker on the conversion feature. The number of shares that the Reporting Person could convert and/or vote at any time, therefore, would be limited to that number of common shares (which when combined with all other common shares then beneficially owned) that would not increase the Reporting Person's beneficial ownership of common stock above 4.99% of the Company's then outstanding common stock.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on August 21, 2024.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 9/15/2024, 1/3 - 8/21/2025, 1/3 - 8/21/2026.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on August 21, 2024.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 9/15/2024, 1/3 - 8/21/2025, 1/3 - 8/21/2026.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on August 21, 2024.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 9/15/2024, 1/3 - 8/21/2025, 1/3 - 8/21/2026.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on August 21, 2024.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 9/15/2024, 1/3 - 8/21/2025, 1/3 - 8/21/2026.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on August 21, 2024.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 9/15/2024, 1/3 - 8/21/2025, 1/3 - 8/21/2026.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on August 21, 2024.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 9/15/2024, 1/3 - 8/21/2025, 1/3 - 8/21/2026.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on August 21, 2024.

The shares subject to the option grant vest in the following amounts on the following dates: 1/3 - 9/15/2024, 1/3 - 8/21/2025, 1/3 - 8/21/2026.

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.0935 to $0.0936, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, for information regarding the number shares at each separate price within the range set forth in this footnote 1.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1239 to $0.1247, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.

42,500 of the shares previously reported are restricted stock units ("RSUs") granted 1/17/2024. Each RSU represents a contingent right to receive one share of ASTI common stock.

One third of the RSU's will vest on each of 3/31/2024, 1/1/2025 and 1/1/2026. Any outstanding and unvested RSU's will accelerate and fully vest upon the earlier of (i) a change of control or (ii) the termination of Ms. Jo's employment for any reason other than (x) by the Company for cause or (y) by Ms. Jo without good reason.

Reflects 4,888 shares withheld by the Issuer to satisfy tax withholding obligations related to an RSU vest on 3/31/2024.

215,000 of the shares previously reported are restricted stock units ("RSUs") granted 1/17/2024. Each RSU represents a contingent right to receive one share of ASTI common stock.

One third of the RSU's will vest on each of 3/31/2024, 1/1/2025 and 1/1/2026. Any outstanding and unvested RSU's will accelerate and fully vest upon the earlier of (i) a change of control or (ii) the termination of Mr. Warley's employment for any reason other than (x) by the Company for cause or (y) by Mr. Warley without good reason.

Reflects 25,184 shares withheld by the Issuer to satisfy tax withholding obligations related to an RSU vest on 3/31/2024.

42,500 of the previously shares reported are restricted stock units ("RSUs") granted 1/17/2024. Each RSU represents a contingent right to receive one share of ASTI common stock.

One third of the RSU's will vest on each of 3/31/2024, 1/1/2025 and 1/1/2026. Any outstanding and unvested RSU's will accelerate and fully vest upon the earlier of (i) a change of control or (ii) the termination of Mr. Gulati's employment for any reason other than (x) by the Company for cause or (y) by Mr. Gulati without good reason.

Reflects 4,888 shares withheld by the Issuer to satisfy tax withholding obligations related to an RSU vest on 3/31/2024.

215,000 of the shares reported are restricted stock units ("RSUs") granted 1/17/2024. Each RSU represents a contingent right to receive one share of ASTI common stock.

One third of the RSU's will vest on each of 3/31/2024, 1/1/2025 and 1/1/2026. Any outstanding and unvested RSU's will accelerate and fully vest upon the earlier of (i) a change of control or (ii) the termination of Mr. Warley's employment for any reason other than (x) by the Company for cause or (y) by Mr. Warley without good reason.